{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:45:48Z","timestamp":1762004748791,"version":"build-2065373602"},"reference-count":22,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2016,1,8]],"date-time":"2016-01-08T00:00:00Z","timestamp":1452211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2016,3]]},"abstract":"\n Aims<\/jats:title>\n \n To compare the pharmacokinetics and pharmacodynamics of dapagliflozin in patients with type 1 diabetes mellitus (\n T1DM<\/jats:styled-content>\n ) versus type 2 diabetes mellitus (\n T2DM<\/jats:styled-content>\n ) in order to explore the potential of dapagliflozin as add\u2010on therapy to insulin in patients with\n T1DM<\/jats:styled-content>\n .\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n Steady\u2010state pharmacokinetics and pharmacodynamics of dapagliflozin (1\u2013100\u2009mg) were evaluated in a meta\u2010analysis of patients with\n T1DM<\/jats:styled-content>\n or\n T2DM<\/jats:styled-content>\n . A model was constructed of the relationship between dapagliflozin systemic exposure and urinary glucose excretion (\n UGE<\/jats:styled-content>\n ) in patients with\n T1DM<\/jats:styled-content>\n versus those with\n T2DM<\/jats:styled-content>\n .\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Data were analysed from 160 patients (\n T1DM<\/jats:styled-content>\n , n\u2009=\u200970;\n T2DM<\/jats:styled-content>\n , n\u2009=\u200990). Dapagliflozin systemic exposure (maximum concentration and area under the curve) increased similarly in a dose\u2010related manner in both patient populations. Dose\u2010dependent increases in 24\u2010h\n UGE<\/jats:styled-content>\n were observed with dapagliflozin in both populations. Unadjusted results showed that with regard to\n UGE<\/jats:styled-content>\n response, dapagliflozin was more potent in patients with\n T1DM<\/jats:styled-content>\n {mean half\u2010maximum effective concentration [\n \n EC\n 50<\/jats:sub>\n <\/jats:styled-content>\n ]\u2009=\u20092.72\u2009ng\/ml [95% confidence interval (\n CI<\/jats:styled-content>\n ) 1.14, 5.08]} than in patients with\n T2DM<\/jats:styled-content>\n [\n \n EC\n 50<\/jats:sub>\n <\/jats:styled-content>\n \u2009=\u200912.2\u2009ng\/ml (95%\n CI<\/jats:styled-content>\n 4.91, 21.1)]. After normalization for baseline fasting plasma glucose, estimated glomerular filtration rate and\n UGE<\/jats:styled-content>\n , however, the\n UGE<\/jats:styled-content>\n potency of dapagliflozin was similar between the two populations [\n T1DM<\/jats:styled-content>\n : mean\n \n EC\n 50<\/jats:sub>\n <\/jats:styled-content>\n , 8.12\u2009ng\/ml (95%\n CI<\/jats:styled-content>\n 2.95, 14.6);\n T2DM<\/jats:styled-content>\n : mean\n \n EC\n 50<\/jats:sub>\n <\/jats:styled-content>\n , 7.75\u2009ng\/ml (95%\n CI<\/jats:styled-content>\n 1.35, 18.1)].\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n Dapagliflozin pharmacokinetics and the predicted\n UGE<\/jats:styled-content>\n dose exposure response to dapagliflozin were similar in patients with\n T1DM<\/jats:styled-content>\n and those with\n T2DM<\/jats:styled-content>\n and suggest that the dapagliflozin dosages currently used for the treatment of\n T2DM<\/jats:styled-content>\n may provide benefit as add\u2010on therapy to insulin in patients with\n T1DM<\/jats:styled-content>\n .\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/dom.12594","type":"journal-article","created":{"date-parts":[[2015,10,29]],"date-time":"2015-10-29T03:49:47Z","timestamp":1446090587000},"page":"236-240","source":"Crossref","is-referenced-by-count":19,"title":["Comparison of the pharmacokinetics and pharmacodynamics of dapagliflozin in patients with type 1 versus type 2 diabetes mellitus"],"prefix":"10.1111","volume":"18","author":[{"given":"W.","family":"Tang","sequence":"first","affiliation":[{"name":"AstraZeneca Gaithersburg MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. A.","family":"Leil","sequence":"additional","affiliation":[{"name":"Bristol\u2010Myers Squibb Princeton NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Johnsson","sequence":"additional","affiliation":[{"name":"AstraZeneca Gothenburg M\u00f6lndal Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. W.","family":"Boulton","sequence":"additional","affiliation":[{"name":"AstraZeneca Gaithersburg MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"LaCreta","sequence":"additional","affiliation":[{"name":"Bristol\u2010Myers Squibb Princeton NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,1,8]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjd.2013.01.020"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOP.0b013e32833a46a7"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2006.00686.x"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.2337\/diaclin.30.1.28"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-1589"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.4066\/AMJ.2014.2181"},{"key":"e_1_2_7_8_1","unstructured":"AstraZeneca and Bristol\u2010Myers SquibbForxiga\u00a0\u2013\u00a0summary of product characteristics 2012. Available from URL:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_\u2010_Product_Information\/human\/002322\/WC500136026.pdf. Accessed 8 April 2013."},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-156-6-201203200-00003"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12187"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01359.x"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.251"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-013-0104-3"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.109.029165"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-012-0016-5"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2010.01314.x"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-011-0098-x"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2955"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.250"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12056"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60407-2"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-0606"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01434.x"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.12594","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.12594","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T23:28:51Z","timestamp":1761866931000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.12594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,8]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["10.1111\/dom.12594"],"URL":"https:\/\/doi.org\/10.1111\/dom.12594","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"type":"print","value":"1462-8902"},{"type":"electronic","value":"1463-1326"}],"subject":[],"published":{"date-parts":[[2016,1,8]]}}}